Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic...
Vous n'êtes pas connecté
- English
- Français
- عربي
- Español
- Deutsch
- Português
- русский язык
- Català
- Italiano
- Nederlands, Vlaams
- Norsk
- فارسی
- বাংলা
- اردو
- Azərbaycan dili
- Bahasa Indonesia
- Հայերեն
- Ελληνικά
- Bosanski jezik
- українська мова
- Íslenska
- Türkmen, Түркмен
- Türkçe
- Shqip
- Eesti keel
- magyar
- Қазақ тілі
- Kalaallisut ; kalaallit oqaasii
- Lietuvių kalba
- Latviešu valoda
- македонски јазик
- Монгол
- Bahasa Melayu ; بهاس ملايو
- ဗမာစာ
- Slovenščina
- тоҷикӣ ; toğikī ; تاجیکی
- ไทย
- O'zbek ; Ўзбек ; أۇزبېك
- Tiếng Việt
- ភាសាខ្មែរ
- རྫོང་ཁ
- Soomaaliga ; af Soomaali
Rubriques :
Maroc - DRUGS.COM - New Drug Approvals - 21/Jun 03:06
Argenx Announces FDA Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
Amsterdam, the Netherlands June 21, 2024 -- argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug...
Articles similaires
Sarepta Therapeutics Announces Expanded US FDA Approval of Elevidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above
drugs.com - 20/Jun 23:06
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare...
FDA Approves Ohtuvayre (ensifentrine) for the Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)
drugs.com - 26/Jun 21:06
LONDON and RALEIGH, N.C., June 26, 2024 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
drugs.com - 01/Jul 06:07
STAMFORD, Conn., July 01, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused...
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase (human recombinant)) injection, solution [argenx US]
nlm.nih.gov - 28/Jun 04:00
Updated Date: Fri, 28 Jun 2024 00:00:00 EDT
VYVGART HYTRULO (efgartigimod alfa and hyaluronidase (human recombinant)) injection, solution [argenx US]
nlm.nih.gov - 28/Jun 04:00
Updated Date: Fri, 28 Jun 2024 00:00:00 EDT
Harmony Biosciences Receives U.S. Food And Drug Administration Approval for Wakix (pitolisant) In Pediatric Patients With Narcolepsy
drugs.com - 24/Jun 23:06
PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug Administration...
Argenx (ARGX) Surges 11.7%: Is This an Indication of Further Gains?
zacks.com - 25/Jun 08:06
Argenx (ARGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock...
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
zacks.com - 12:34
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...
Regeneron (REGN), SNY Win EC Approval for Dupixent for COPD
zacks.com - 12:06
Regeneron (REGN) and partner Sanofi get approval for their blockbuster drug Dupixent for the chronic obstructive pulmonary disease indication in the...
Les derniers communiqués
-
Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
-
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022